Voyager Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Voyager Therapeutics - overview
Established
2014
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Voyager Therapeutics specializes in innovative gene therapies for neurological diseases, utilizing advanced delivery systems to enhance treatment efficacy and improve patient outcomes in areas such as Alzheimer's and Parkinson's disease. Founded in 2014, Voyager Therapeutics is based in Cambridge, US, and focuses on developing genetic medicines to treat neurological disorders. The company has undergone strategic pivots to enhance its product offerings and has raised a total of USD 70 mn through funding rounds, with the latest being an IPO on November 10, 2015. The company was co-founded by Steve Paul, a notable figure in the biotech sector, and is currently led by CEO Al Sandrock.
Voyager Therapeutics is focused on the development of innovative gene therapies aimed at treating a range of neurological diseases. The company’s primary product offerings include genetic medicines targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other central nervous system disorders. These therapies utilize the TRACER™ (Translationally-Optimized AAV Capsid Engineering) platform, which enables the creation of novel AAV capsids designed for efficient delivery across the blood-brain barrier. The end users of these therapies are primarily patients suffering from these debilitating conditions, while the company collaborates with various healthcare providers and research institutions to bring these products to market.
Voyager Therapeutics operates primarily in North America and Europe, focusing on regions with a high prevalence of neurological disorders. In the most recent year, Voyager Therapeutics reported a revenue of USD 80. 00 mn for 2024, alongside an EBITDA of USD -70. 59 mn.
The company generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations, which include milestone payments and royalties from product sales. Their flagship product, VY7523 for Alzheimer’s disease, is expected to contribute significantly to these financial arrangements as it advances through clinical trials. Voyager Therapeutics plans to leverage recent funding of USD 70 mn raised during their IPO to further develop their pipeline of gene therapies, particularly focusing on VY7523 for Alzheimer’s disease and expanding their product offerings. The company aims to launch new products aimed at treating various neurological disorders in the coming years.
Additionally, Voyager Therapeutics is actively exploring opportunities to expand into new geographic markets, particularly targeting Europe and Asia, with initiatives expected to commence within the next 2 years.
Current Investors
Third Rock Ventures, Wellington Management, Casdin Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Epidemiology
Website
www.voyagertherapeutics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Voyager Therapeutics - timeline of key events
Voyager Therapeutics - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 17,334,000 | 14,220,000 | 10,135,000 | 7,619,000 | 104,391,000 | 171,128,000 | 37,415,000 | 40,907,000 | - | - | - |
| % Revenue Growth (YoY) | - | (18.0%) | (28.7%) | (24.8%) | 1270.1% | 63.9% | (78.1%) | 9.3% | - | - | - |
| EBITDA (USD) | (19,202,000) | (39,991,000) | (70,292,000) | (91,141,000) | (52,498,000) | 31,228,000 | (68,104,000) | (44,662,000) | - | - | - |
| Operating Income (USD) | (20,254,000) | (41,299,000) | (71,863,000) | (91,095,000) | (51,679,000) | 27,384,000 | (73,618,000) | (50,837,000) | - | - | - |
| Operating Margin | (116.8%) | (290.4%) | (709.1%) | (1195.6%) | (49.5%) | 16.0% | (196.8%) | (124.3%) | - | - | - |
| % EBITDA Margin | (110.8%) | (281.2%) | (693.6%) | (1196.2%) | (50.3%) | 18.2% | (182.0%) | (109.2%) | - | - | - |
| NET Income (USD) | (29,672,000) | (40,193,000) | (70,698,000) | (88,288,000) | (43,597,000) | 36,741,000 | (71,197,000) | (46,408,000) | - | - | - |
| % Net Margin | (171.2%) | (282.7%) | (697.6%) | (1158.8%) | (41.8%) | 21.5% | (190.3%) | (113.4%) | - | - | - |
Voyager Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.